Holdings in Company

Paris, France and Camberley, UK – 18 February 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex SA (“Biosynex”) on 18 February 2022 that, as at 14 February 2022, Biosynex’s holding in the Company on a voting and capital basis is 4.04%

Visit Page

Approval of the first direct-to-PCR COVID-19 test in the UK under CTDA legislation

Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate® COVID-19 2G Real-Time PCR test has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) (Amendment) Regulations 2021 (“CTDA”). http://novacyt.com/wp-content/uploads/2022/02/Novacyt-CTDA-approval-of-PROmate-2G.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 15 February 2022 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified by Biosynex SA (“Biosynex”) on 14 February 2022 that, as at 10 February 2022, Biosynex’s holding in the Company on a voting and capital basis is 3.0012% (2,119,627

Visit Page